BLAU3 Stock Overview
Blau Farmacêutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Blau Farmacêutica S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$16.04 |
| 52 Week High | R$31.48 |
| 52 Week Low | R$14.18 |
| Beta | 0.17 |
| 1 Month Change | -0.93% |
| 3 Month Change | -9.22% |
| 1 Year Change | -44.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.97% |
Recent News & Updates
Recent updates
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Shareholder Returns
| BLAU3 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -4.2% | 0.6% | -0.4% |
| 1Y | -44.0% | -8.1% | 6.7% |
Return vs Industry: BLAU3 underperformed the BR Biotechs industry which returned -8.1% over the past year.
Return vs Market: BLAU3 underperformed the BR Market which returned 6.5% over the past year.
Price Volatility
| BLAU3 volatility | |
|---|---|
| BLAU3 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.6% |
Stable Share Price: BLAU3 is more volatile than 75% of BR stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BLAU3's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marcelo Hahn | https://www.blau.com |
Blau Farmacêutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. The company’s medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics. It also offers biological drugs; oral and injectable drugs for treating cancer; specialized treatments for infectious diseases; and prescription and non-prescription drugs, including dermo-medicines, condoms, and others for retail and non-retail markets.
Blau Farmacêutica S.A. Fundamentals Summary
| BLAU3 fundamental statistics | |
|---|---|
| Market Cap | R$2.85b |
| Earnings (TTM) | R$317.12m |
| Revenue (TTM) | R$1.35b |
9.0x
P/E Ratio2.1x
P/S RatioIs BLAU3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLAU3 income statement (TTM) | |
|---|---|
| Revenue | R$1.35b |
| Cost of Revenue | R$819.77m |
| Gross Profit | R$532.08m |
| Other Expenses | R$214.97m |
| Earnings | R$317.12m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.78 |
| Gross Margin | 39.36% |
| Net Profit Margin | 23.46% |
| Debt/Equity Ratio | 28.7% |
How did BLAU3 perform over the long term?
See historical performance and comparison